Drug Trial Radar · NCT06464991
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Mar 27, 2024
Primary completion
Aug 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM) who have received 1-2 lines of prior therapy. Approximately 240 subjects from China and, in accordance with Japanese regulatory requirements, approximately 20 additional subjects from Japan are planned to be enrolled in this study, for a total of approximately 260 subjects.
Conditions
- Multiple Myeloma
Interventions
Equecabtagene Autoleucel InjectionDrug
dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
DaratumumabDrug
dosage form: injection or subcutaneous injection. For intravenous administration: dose level 16 mg/kg, 28 days/cycle for the DPd regimen * Cycle1-2: D1, D8, D15, D22; * Cycle3-6: D1, D15; * above Cycle7: D1; body weight should be recalculated on D1 of the current cycle if it differs from baseline by more than +/-10%. For subcutaneous administration: fixed dose of 1,800 mg. The formulation and route of administration (intravenous or subcutaneous) should be selected according to the clinical practice in the country where the study is conducted.
PomalidomideDrug
dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
BortezomibDrug
dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8.
DexamethasoneDrug
dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 monthsTime frame: 12 months (+/-3 months) post-randomization
- Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)Time frame: up to 5 years from randomization
Locations
41 sites in 2 countries. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, China
Beijing GoBoard Boren Hospital
Beijing, China
Fu Xing Hospital, Capital Medical University
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
People's Hospital of Peking University
Beijing, China
The first hospital of Jilin University
Changchun, China
West China School of Medicine, West China Hospital of Sichuan University
Chengdu, China
Xinqiao Hospital of AMU
Chongqing, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Sun Yat-sen University Cancer Centre
Guangzhou, China
Zhujiang Hospital of Southern Medical University Guangdong
Guangzhou, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, China
The Second Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, China
Qilu Hospital of Shangdong University
Jinan, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
The Affiliated People's Hospital of Ningbo University
Ningbo, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University
Zhengzhou, China
Kyushu University Hospital
Fukuoka, Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Hiroshima, Japan
Hokkaido University Hospital
Hokkaido, Japan
Hyogo Medical University Hospital
Hyōgo, Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan
Nagoya City University Hospital
Nagoya, Japan
Kindai University Hospital
Osaka, Japan
The University of Osaka Hospital
Osaka, Japan
Jichi Medical University Hospital
Tochigi, Japan
Institute of Science Tokyo Hospital
Tokyo, Japan
Japanese Red Cross Medical Center
Tokyo, Japan
Nihon University Itabashi Hospital
Tokyo, Japan
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.